ProQR Therapeutics N.V. (PRQR) DCF Valuation

ProQR Therapeutics N.V. (PRQR) DCF Valuation
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

ProQR Therapeutics N.V. (PRQR) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of ProQR Therapeutics N.V.? Our PRQR DCF Calculator integrates real-world data with extensive customization options, allowing you to refine your forecasts and enhance your investment strategies.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019
AY2
2020
AY3
2021
AY4
2022
AY5
2023
FY1
2024
FY2
2025
FY3
2026
FY4
2027
FY5
2028
Revenue 2.0 .0 1.4 4.2 6.8 7.8 9.0 10.4 12.0 13.9
Revenue Growth, % 0 -100 0 198.15 61.36 15.34 15.34 15.34 15.34 15.34
EBITDA -181.7 -142.3 -57.3 -58.9 -25.1 -4.7 -5.4 -6.3 -7.2 -8.3
EBITDA, % -9015.42 100 -4058.2 -1398.56 -369.93 -60 -60 -60 -60 -60
Depreciation 2.1 2.3 2.5 2.6 2.6 6.3 7.2 8.3 9.6 11.1
Depreciation, % 105.85 100 178.87 61.32 38.58 79.98 79.98 79.98 79.98 79.98
EBIT -183.8 -144.6 -59.8 -61.4 -27.7 -4.7 -5.4 -6.3 -7.2 -8.3
EBIT, % -9121.27 100 -4237.07 -1459.89 -408.5 -60 -60 -60 -60 -60
Total Cash 116.7 79.1 195.5 98.8 124.0 7.8 9.0 10.4 12.0 13.9
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .4 .0 59.7 1.3
Account Receivables, % 0 100 0 1417.79 19.47
Inventories .4 .4 .3 .0 .0 2.2 2.5 2.9 3.3 3.8
Inventories, % 17.59 100 19.68 0.17005 0 27.49 27.49 27.49 27.49 27.49
Accounts Payable .5 .2 .2 .4 1.6 2.7 3.1 3.6 4.1 4.7
Accounts Payable, % 23.02 100 14.11 9.71 23.66 34.1 34.1 34.1 34.1 34.1
Capital Expenditure -.6 -1.0 -.5 -.7 -1.4 -1.6 -1.9 -2.2 -2.5 -2.9
Capital Expenditure, % -30.01 100 -35.75 -17.54 -21.05 -20.87 -20.87 -20.87 -20.87 -20.87
Tax Rate, % -1.1 -1.1 -1.1 -1.1 -1.1 -1.1 -1.1 -1.1 -1.1 -1.1
EBITAT -184.2 -145.0 -59.9 -61.5 -28.0 -4.7 -5.4 -6.3 -7.2 -8.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -182.6 -144.4 -57.4 -118.9 32.7 -3.3 -.5 -.6 -.7 -.8
WACC, % 5.68 5.68 5.68 5.68 5.68 5.68 5.68 5.68 5.68 5.68
PV UFCF
SUM PV UFCF -5.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -1
Terminal Value -22
Present Terminal Value -17
Enterprise Value -22
Net Debt -103
Equity Value 81
Diluted Shares Outstanding, MM 81
Equity Value Per Share 1.00

What You Will Get

  • Editable Forecast Inputs: Easily adjust assumptions (growth %, margins, WACC) to develop various scenarios.
  • Real-World Data: ProQR Therapeutics N.V. (PRQR) financial data pre-loaded to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
  • Customizable and Professional: A sleek Excel model that can be tailored to meet your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and optimizing efficiency.

Key Features

  • Comprehensive Financial Data: Gain access to precise pre-loaded historical figures and future forecasts for ProQR Therapeutics N.V. (PRQR).
  • Adjustable Forecast Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
  • Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow evaluations.
  • User-Friendly Dashboard: Clear and informative charts and summaries to help you interpret your valuation findings.
  • Designed for All Levels: An accessible, intuitive layout tailored for investors, CFOs, and consultants alike.

How It Works

  • 1. Download the Template: Obtain and open the Excel file containing ProQR Therapeutics N.V. (PRQR) preloaded data.
  • 2. Adjust Key Assumptions: Modify essential inputs such as growth projections, WACC, and capital expenditures.
  • 3. Instant Results: The DCF model automatically computes intrinsic value and NPV based on your inputs.
  • 4. Explore Different Scenarios: Evaluate various forecasts to understand diverse valuation results.
  • 5. Present with Assurance: Deliver professional valuation analyses to reinforce your decision-making.

Why Choose This Calculator for ProQR Therapeutics N.V. (PRQR)?

  • User-Friendly Interface: Tailored for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters to suit your specific analysis needs.
  • Real-Time Feedback: Observe immediate updates to ProQR’s valuation as you change inputs.
  • Preloaded Data: Comes with ProQR’s latest financial information for swift evaluations.
  • Relied Upon by Experts: Utilized by investors and analysts for strategic decision-making.

Who Should Use This Product?

  • Biotech Investors: Develop comprehensive and accurate valuation models for assessing ProQR Therapeutics (PRQR) investments.
  • Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the biotech sector.
  • Consultants and Advisors: Deliver precise valuation insights for clients considering ProQR Therapeutics (PRQR) stock.
  • Students and Educators: Utilize real-world biotechnology data to learn and teach financial modeling techniques.
  • Healthcare Enthusiasts: Gain insights into how biotech companies like ProQR Therapeutics (PRQR) are valued in the market.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled ProQR Therapeutics N.V. (PRQR) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for ProQR Therapeutics N.V. (PRQR).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.